Effect of HMGB1 on human hepatoma cell line-HepG2 proliferation.
10.3969/j.issn.1672-7347.2010.05.008
- Author:
Xinchun HE
1
;
Xuegong FAN
;
Rongrong ZHOU
;
Haichao WANG
Author Information
1. Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Cell Proliferation;
drug effects;
Cyclin D1;
genetics;
metabolism;
HMGB1 Protein;
pharmacology;
Hep G2 Cells;
Humans;
Proliferating Cell Nuclear Antigen;
genetics;
metabolism;
RNA, Messenger;
genetics;
metabolism;
Recombinant Proteins;
pharmacology;
Reverse Transcriptase Polymerase Chain Reaction
- From:
Journal of Central South University(Medical Sciences)
2010;35(5):451-457
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of high mobility group box-1 protein (HMGB1) on the proliferative activity of human hepatoma cell line HepG2 and its potential regulating mechanism.
METHODS:The cultured HepG2 cells were treated with recombinant HMGB1 (0, 10, 50, and 100 ng/mL, respectively) for 24 h. Cell proliferation was observed by MTT analysis. Western blot and reverse transcriptase-polymerase chain reaction were used to detect the expression of proliferating cell nuclear antigen (PCNA) and cyclin D1 protein and mRNA, respectively.
RESULTS:Compared with the control group, HMGB1 at 10, 50, and 100 ng/mL obviously increased HepG2 cells proliferation, cyclin D1 and PCNA protein and mRNA expression after the treatment for 24 h, respectively (P<0.05). Anti-HMGB1 significantly inhibited the proliferation and cyclin D1 and PCNA mRNA and protein expression of HMGB1 on HepG2 cells (P<0.05).
CONCLUSION:Proliferation of HMGB1 on HepG2 cells may be associated with increasing cyclin D1 and PCNA expression. Anti-HMGB1 may have a therapeutic effect on hepatocellular carcinoma.
